GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed Price. Currency in GBp
1,523.50
-12.50 (-0.81%)
At close: 5:10PM BST
Stock chart is not supported by your current browser
Previous Close1,536.00
Open1,543.00
Bid1,500.00 x 175400
Ask1,525.00 x 417900
Day's Range1,517.50 - 1,544.50
52 Week Range1,444.00 - 1,724.50
Volume8,410,188
Avg. Volume8,011,472
Market Cap73.97B
Beta1.15
PE Ratio (TTM)38.96
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.01 (5.14%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Reuters4 hours ago

    Britain backs GSK's gene therapy for 'bubble boy' syndrome

    Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment. Britain's National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem cell transplant therapy.

  • FDA approves better vaccine against painful shingles virus
    Associated Press2 days ago

    FDA approves better vaccine against painful shingles virus

    U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus.

  • Reuters2 days ago

    GlaxoSmithKline adult shingles vaccine wins U.S. approval

    Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co (MRK.N). The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data. Glaxo said the U.S. Centers for Disease Control and Prevention's advisory committee on immunization practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday.

  • Reuters2 days ago

    GlaxoSmithKline adult shingles vaccine wins U.S. approval

    The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday. Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co. The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data.

  • Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?
    Zacks3 days ago

    Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

    The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

  • 3 High-Yield Pharmaceutical Stocks
    Motley Fool3 days ago

    3 High-Yield Pharmaceutical Stocks

    High-yield pharma stocks are rare, but these three offer comparatively fat payouts.

  • China Biotech Promise Struggles to Keep Foreign Innovators
    Bloomberg3 days ago

    China Biotech Promise Struggles to Keep Foreign Innovators

    As money rushes into China’s fledgling biotechnology sector, Eli Lilly & Co. and other foreign drugmakers are scaling back.

  • Reuters4 days ago

    China biotech's 'coming out party' masks long road ahead

    LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (HCM.L), Beigene (BGNE.O) and Zai Lab (ZLAB.O) have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (AZN.L).

  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacks4 days ago

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • Market Realist5 days ago

    What GlaxoSmithKline’s 3Q17 Performance Tells Us

    GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

  • Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
    Zacks6 days ago

    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

  • Reuters9 days ago

    GlaxoSmithKline's shingles vaccine gets approval in Canada

    (Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...

  • CNBC10 days ago

    Pharma companies are starting to recruit top talent from tech giants like Google and LinkedIn

    Pharma companies are recruiting technologists to help speed up their drug discovery and development processes.

  • The Wall Street Journal11 days ago

    [$$] Ebola Vaccines Show Promise in New Study

    The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...

  • Pfizer weighs $15 bln sale of consumer healthcare business
    Reuters12 days ago

    Pfizer weighs $15 bln sale of consumer healthcare business

    The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.

  • May to consult business leaders on Brexit
    Reuters14 days ago

    May to consult business leaders on Brexit

    Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.

  • 3 High-Yield Healthcare Stocks
    Motley Fool15 days ago

    3 High-Yield Healthcare Stocks

    If you're on the hunt for above-average yields, these three healthcare stocks should be on your radar.

  • Reuters16 days ago

    FTSE at two-month peak as sterling falters

    British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning groups such as pharma stocks. The FTSE 100 index (.FTSE) closed 0.2 percent up at 7,522.87 points, with Britain's pound on track for its worst week in a year as the Prime Minister hit back at a plot to topple her, saying she would provide "calm leadership" to the country. "The talk of a leadership plot against the Prime Minister is eroding the pound's value and propping up the FTSE 100," CMC Markets analyst David Madden wrote in a note to clients.

  • Market Realist18 days ago

    Changes in GlaxoSmithKline’s Valuation

    As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.

  • Drug industry gives up legal battle over new UK cost curbs
    Reuters18 days ago

    Drug industry gives up legal battle over new UK cost curbs

    Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.

  • Market Realist18 days ago

    Performance of GlaxoSmithKline’s Consumer Healthcare Segment

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.

  • Market Realist18 days ago

    Quarterly Performance of GlaxoSmithKline’s Vaccines Segment

    The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16.

  • Capital Cube18 days ago

    GlaxoSmithKline Plc – Value Analysis (LONDON:GSK) : October 4, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives GlaxoSmithKline Plc a score of 63. Our analysis is based on comparing GlaxoSmithKline Plc with the following peers – AstraZeneca PLC, Shire PLC, Hikma Pharmaceuticals Plc and Consort Medical Plc (AZN-GB, SHP-GB, HIK-GB and CSRT-GB). Investment Outlook GlaxoSmithKline Plc has a fundamental score of 63 and has ... Read more (Read more...)

  • Market Realist19 days ago

    Quarterly Performance for GlaxoSmithKline’s HIV Business

    HIV products reported a 29.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by the strong performances of Tivicay and Triumeq.